All In Biotech

Drug Trial Radar · NCT03873324

Safety and Pharmacokinetics Study of CPL500036 Compound in Healthy Volunteers

One Centre Single Ascending Dose and Double Blind Multiple Ascending Dose, Safety and Pharmacokinetics Phase I Study of CPL500036 Compound in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Oct 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

Dec 20, 2018

Primary completion

Sep 16, 2019

Study completion Sep 16, 2019

Sponsor

Lead sponsor
Celon Pharma SAIndustry
Sponsor type
Industry
Collaborators
National Center for Research and Development, Poland
First posted
Mar 13, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The planned study is to determine the safety and pharmacokinetic properties of CPL500036 compound after single and multiple (two weeks) administration in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

  • CPL500036 compoundDrug

    IMP is a capsule with CPL500036 as an Active Pharmaceutical Ingredient (API).

  • PlaceboDrug

    matching placebo capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determination of maximum tolerated dose (MTD) or administration of the maximum dose provided in the protocol after single and multiple oral administration of IMP.Time frame: up to 24 hours after single administration of IMP in PART A and up to 24 hours after the last IMP administration in PART B
  2. Safety and tolerability of IMP after single and multiple oral administration based on laboratory values, vital signs, ECG, physical examinations and Adverse Events monitoring.Time frame: up to 14 days in PART A and up to 28 days in PART B of the study

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • BioResearch Group Sp. z o.o.

    Kajetany, Nadarzyn, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.